14/02/2024
Casgevy and Lyfgenia: Gene Therapies for Sickle Cell
The U.S. Food and Drug Administration (FDA) recently approved two groundbreaking gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease (SCD) in patients 12 years and older. These therapies represent the first cell-based gene treatments for SCD, a group of inherited blood disorders affecting around 100,000 people in the U.S., particularly African and Hispanic Americans. Casgevy is a cell-based gene therapy that utilizes CRISPR/Cas9, a novel genome editing technology, to modify patients' hematopoietic stem cells. This modification increases the levels of HbF, which prevents the sickling of red blood cells.
https://youtu.be/oqaZRUv7WSE?si=wUiDZrXDkCzJk3kG
On the other hand, Lyfgenia is a cell-based gene therapy that uses a lentiviral vector to genetically modify patients' blood stem cells to produce HbAT87Q, a type of hemoglobin that reduces the sickling of red blood cells. The approval of these gene therapies marks a significant advancement in the treatment of SCD, offering a potential one-time fix for the disease. Both therapies were granted Priority Review, Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy designations by the FDA. The safety and effectiveness of Casgevy and Lyfgenia were evaluated in rigorous clinical trials, with both therapies demonstrating promising results in reducing vaso-occlusive events (VOEs) and improving patients' quality of life.
The gene therapies are not without risks, as some patients experienced side effects such as mouth sores, low blood cell levels, and febrile neutropenia. Additionally, a black box warning is included in the label for Lyfgenia due to the risk of hematologic malignancy, and patients receiving this therapy require lifelong monitoring for these malignancies.
The process to receive either of these gene therapies involves multiple hospital visits and chemotherapy. Patients who received Casgevy or Lyfgenia will be followed in long-term studies to evaluate the safety and effectiveness of each treatment.
The approval of Casgevy and Lyfgenia offers new hope for individuals with SCD, providing potentially curative options that were previously limited. While the gene therapies represent a significant medical advance, their uptake is expected to be gradual, with initial availability at a limited number of treatment centers across the country. The FDA's approval of these gene therapies reflects a commitment to facilitating the development of safe and effective treatments for conditions with severe unmet medical needs.
In summary, the approval of Casgevy and Lyfgenia represents a major milestone in the treatment of SCD, offering potential one-time gene-based treatments for patients 12 years and older. These therapies have shown promising results in reducing VOEs and improving patients' quality of life, although they are not without associated risks. The availability of these gene therapies at treatment centers is expected to expand over time, providing new hope for individuals affected by SCD.
The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treat...
